RU2018136877A - Способы раннего вмешательства для профилактики или улучшения состояния токсичности - Google Patents
Способы раннего вмешательства для профилактики или улучшения состояния токсичности Download PDFInfo
- Publication number
- RU2018136877A RU2018136877A RU2018136877A RU2018136877A RU2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A
- Authority
- RU
- Russia
- Prior art keywords
- therapy
- treatment
- individual
- paragraphs
- crs
- Prior art date
Links
- 230000001988 toxicity Effects 0.000 title claims 13
- 231100000419 toxicity Toxicity 0.000 title claims 13
- 230000002265 prevention Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 claims 120
- 238000002560 therapeutic procedure Methods 0.000 claims 113
- 238000000034 method Methods 0.000 claims 85
- 206010052015 cytokine release syndrome Diseases 0.000 claims 77
- 239000003795 chemical substances by application Substances 0.000 claims 65
- 206010037660 Pyrexia Diseases 0.000 claims 44
- 206010029350 Neurotoxicity Diseases 0.000 claims 39
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 39
- 230000007135 neurotoxicity Effects 0.000 claims 39
- 231100000228 neurotoxicity Toxicity 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 38
- 238000002659 cell therapy Methods 0.000 claims 38
- 208000024891 symptom Diseases 0.000 claims 34
- 150000003431 steroids Chemical class 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 18
- 102000005962 receptors Human genes 0.000 claims 15
- 108020003175 receptors Proteins 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 14
- 238000009169 immunotherapy Methods 0.000 claims 12
- 229960003989 tocilizumab Drugs 0.000 claims 12
- 230000000977 initiatory effect Effects 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 229960003957 dexamethasone Drugs 0.000 claims 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 8
- -1 IFNγ Proteins 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 230000001754 anti-pyretic effect Effects 0.000 claims 6
- 239000002221 antipyretic Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000000069 prophylactic effect Effects 0.000 claims 6
- 208000001953 Hypotension Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000012866 low blood pressure Diseases 0.000 claims 5
- 231100000331 toxic Toxicity 0.000 claims 5
- 230000002588 toxic effect Effects 0.000 claims 5
- 206010010904 Convulsion Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 4
- 230000000139 costimulatory effect Effects 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 238000011269 treatment regimen Methods 0.000 claims 4
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 3
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 3
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims 3
- 108010002352 Interleukin-1 Proteins 0.000 claims 3
- 102000000589 Interleukin-1 Human genes 0.000 claims 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 3
- 108090000174 Interleukin-10 Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 3
- 102000004889 Interleukin-6 Human genes 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 3
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 3
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 3
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 102000003675 cytokine receptors Human genes 0.000 claims 3
- 108010057085 cytokine receptors Proteins 0.000 claims 3
- 229960000390 fludarabine Drugs 0.000 claims 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims 3
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims 3
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 claims 3
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229950010006 olokizumab Drugs 0.000 claims 3
- 230000002085 persistent effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229950006348 sarilumab Drugs 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 230000003044 adaptive effect Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 239000005526 vasoconstrictor agent Substances 0.000 claims 2
- 230000003313 weakening effect Effects 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 208000007774 Broca Aphasia Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 238000011467 adoptive cell therapy Methods 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 230000035487 diastolic blood pressure Effects 0.000 claims 1
- 208000010771 expressive aphasia Diseases 0.000 claims 1
- 231100000171 higher toxicity Toxicity 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000005399 mechanical ventilation Methods 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000008533 pain sensitivity Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311906P | 2016-03-22 | 2016-03-22 | |
| US62/311,906 | 2016-03-22 | ||
| US201662417287P | 2016-11-03 | 2016-11-03 | |
| US62/417,287 | 2016-11-03 | ||
| US201662429722P | 2016-12-02 | 2016-12-02 | |
| US62/429,722 | 2016-12-02 | ||
| PCT/US2017/023676 WO2017165571A1 (en) | 2016-03-22 | 2017-03-22 | Early intervention methods to prevent or ameliorate toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018136877A true RU2018136877A (ru) | 2020-04-22 |
Family
ID=58609964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018136877A RU2018136877A (ru) | 2016-03-22 | 2017-03-22 | Способы раннего вмешательства для профилактики или улучшения состояния токсичности |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US11518814B2 (enExample) |
| EP (3) | EP4015536A1 (enExample) |
| JP (3) | JP7048571B2 (enExample) |
| KR (1) | KR20190021200A (enExample) |
| CN (1) | CN109476743A (enExample) |
| AU (2) | AU2017238218B2 (enExample) |
| BR (1) | BR112018069251A2 (enExample) |
| CA (1) | CA3018588A1 (enExample) |
| ES (1) | ES2907557T3 (enExample) |
| MA (2) | MA44486A (enExample) |
| MX (1) | MX2018011480A (enExample) |
| RU (1) | RU2018136877A (enExample) |
| WO (1) | WO2017165571A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG10202104804PA (en) | 2014-10-20 | 2021-06-29 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| ES2901795T3 (es) | 2015-12-04 | 2022-03-23 | Juno Therapeutics Inc | Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular |
| JP7048571B2 (ja) | 2016-03-22 | 2022-04-05 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 毒性を予防または改善するための早期介入法 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| RU2019120398A (ru) * | 2016-12-03 | 2021-01-12 | Джуно Терапьютикс, Инк. | Способы определения дозировки cart-клеток |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CA3053539A1 (en) | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2019109053A1 (en) * | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| AU2019209432A1 (en) * | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| BR122023022189A2 (pt) | 2018-02-16 | 2024-02-20 | Incyte Corporation | Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019170845A1 (en) * | 2018-03-09 | 2019-09-12 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| CN111989344A (zh) * | 2018-03-09 | 2020-11-24 | 科济生物医药（上海）有限公司 | 用于治疗肿瘤的方法和组合物 |
| US20210263045A1 (en) * | 2018-04-06 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| WO2021028469A1 (en) * | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| ES2970382T3 (es) * | 2019-08-14 | 2024-05-28 | Rigel Pharmaceuticals Inc | Método para bloquear o mejorar el síndrome de liberación de citocinas |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| US20230366893A1 (en) * | 2020-09-29 | 2023-11-16 | Washington University | Methods to determine risk of neurotoxicity |
| WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| DK4333840T3 (da) | 2021-05-03 | 2025-11-24 | Incyte Corp | Jak1-vejinhibitorer til behandling af prurigo nodularis |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US265209A (en) | 1882-09-26 | Automatic feeder for perforators | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| CA2147466A1 (en) | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2007147623A2 (en) * | 2006-06-22 | 2007-12-27 | Cellact Pharma Gmbh | A novel target in the treatment of cytokine release syndrome |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| CA2810465C (en) * | 2010-09-16 | 2018-10-02 | Baliopharm Ag | Anti-hutnfr1 antibody |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| ES2778701T3 (es) * | 2012-07-13 | 2020-08-11 | The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer | Gestión de toxicidad para la actividad antitumoral de CAR |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| IL303543A (en) * | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017035362A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| JP7048571B2 (ja) | 2016-03-22 | 2022-04-05 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 毒性を予防または改善するための早期介入法 |
| CN120285179A (zh) | 2016-07-15 | 2025-07-11 | 诺华股份有限公司 | 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征 |
-
2017
- 2017-03-22 JP JP2019500746A patent/JP7048571B2/ja active Active
- 2017-03-22 KR KR1020187030514A patent/KR20190021200A/ko not_active Withdrawn
- 2017-03-22 BR BR112018069251A patent/BR112018069251A2/pt not_active IP Right Cessation
- 2017-03-22 RU RU2018136877A patent/RU2018136877A/ru not_active Application Discontinuation
- 2017-03-22 MA MA044486A patent/MA44486A/fr unknown
- 2017-03-22 EP EP21207779.6A patent/EP4015536A1/en active Pending
- 2017-03-22 EP EP24221056.5A patent/EP4545143A3/en active Pending
- 2017-03-22 MA MA71266A patent/MA71266A/fr unknown
- 2017-03-22 MX MX2018011480A patent/MX2018011480A/es unknown
- 2017-03-22 AU AU2017238218A patent/AU2017238218B2/en active Active
- 2017-03-22 US US16/087,488 patent/US11518814B2/en active Active
- 2017-03-22 CA CA3018588A patent/CA3018588A1/en active Pending
- 2017-03-22 WO PCT/US2017/023676 patent/WO2017165571A1/en not_active Ceased
- 2017-03-22 ES ES17719044T patent/ES2907557T3/es active Active
- 2017-03-22 CN CN201780031706.6A patent/CN109476743A/zh active Pending
- 2017-03-22 EP EP17719044.4A patent/EP3433276B1/en not_active Revoked
-
2022
- 2022-03-24 JP JP2022047991A patent/JP7528143B2/ja active Active
- 2022-12-02 US US18/061,196 patent/US11760804B2/en active Active
- 2022-12-05 US US18/061,939 patent/US20230212298A1/en active Pending
-
2023
- 2023-06-06 US US18/329,987 patent/US12098208B2/en active Active
-
2024
- 2024-07-24 AU AU2024205049A patent/AU2024205049A1/en active Pending
- 2024-07-24 JP JP2024118592A patent/JP2024156736A/ja active Pending
- 2024-09-09 US US18/828,243 patent/US20240425608A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019509351A (ja) | 2019-04-04 |
| EP4015536A1 (en) | 2022-06-22 |
| CA3018588A1 (en) | 2017-09-28 |
| MA71266A (fr) | 2025-04-30 |
| MA44486A (fr) | 2019-01-30 |
| ES2907557T3 (es) | 2022-04-25 |
| AU2024205049A1 (en) | 2024-08-15 |
| EP4545143A2 (en) | 2025-04-30 |
| MX2018011480A (es) | 2019-03-28 |
| US20230212298A1 (en) | 2023-07-06 |
| US12098208B2 (en) | 2024-09-24 |
| WO2017165571A1 (en) | 2017-09-28 |
| EP4545143A3 (en) | 2025-07-23 |
| JP7528143B2 (ja) | 2024-08-05 |
| BR112018069251A2 (pt) | 2019-01-22 |
| AU2017238218B2 (en) | 2024-05-02 |
| JP2022088489A (ja) | 2022-06-14 |
| JP7048571B2 (ja) | 2022-04-05 |
| KR20190021200A (ko) | 2019-03-05 |
| US20190112379A1 (en) | 2019-04-18 |
| US11518814B2 (en) | 2022-12-06 |
| US20230322937A1 (en) | 2023-10-12 |
| AU2017238218A1 (en) | 2018-10-11 |
| CN109476743A (zh) | 2019-03-15 |
| US20230091447A1 (en) | 2023-03-23 |
| JP2024156736A (ja) | 2024-11-06 |
| US11760804B2 (en) | 2023-09-19 |
| US20240425608A1 (en) | 2024-12-26 |
| EP3433276B1 (en) | 2021-12-22 |
| EP3433276A1 (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018136877A (ru) | Способы раннего вмешательства для профилактики или улучшения состояния токсичности | |
| Xiao et al. | Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies | |
| Maronese et al. | Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments | |
| Chandran et al. | Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial | |
| Shimabukuro-Vornhagen et al. | Cytokine release syndrome | |
| Shao et al. | Targeted treatment for erythrodermic psoriasis: rationale and recent advances | |
| AU2018206705B2 (en) | Use of low dose IL-2 for treating autoimmune - related or inflammatory disorders | |
| JP2024156736A5 (enExample) | ||
| Sfriso et al. | Adult-onset Still’s disease: molecular pathophysiology and therapeutic advances | |
| Bauditz et al. | Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. | |
| Luan et al. | Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis | |
| Park et al. | Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis | |
| Iliou et al. | Adult-onset Still’s disease: clinical, serological and therapeutic considerations | |
| US20100135998A1 (en) | Combination therapy for treatment of immune disorders | |
| Baur et al. | Dasatinib for treatment of CAR T-cell therapy-related complications | |
| Cunha et al. | Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice | |
| US20150150968A1 (en) | Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections | |
| Chatila et al. | Primary combined immunodeficiency resulting from defective transcription of multiple T-cell lymphokine genes. | |
| Kulmatycki et al. | Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response | |
| Baek et al. | Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis | |
| Koda et al. | Sema4A inhibits the therapeutic effect of IFN-β in EAE | |
| Tchao et al. | AB0432 efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study | |
| Wang et al. | Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis | |
| Melchior et al. | Temporal analysis of cytokine gene expression during infiltration of porcine neuronal grafts implanted into the rat brain | |
| CN112656801B (zh) | 孕激素在制备治疗细胞因子释放综合征的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200323 |